Literature DB >> 31240744

Quality of life in children with severe forms of idiopathic nephrotic syndrome in stable remission-A cross-sectional study.

Aphaia Roussel1, Jean-Daniel Delbet1, Laurianne Micheland2, Georges Deschênes3, Stephane Decramer4, Tim Ulinski1,5.   

Abstract

AIM: Severe forms of idiopathic nephrotic syndrome (INS) require immunosuppressive therapy: oral treatment or intravenous therapy (rituximab, RTX). The main objective was to describe quality of life (QOL) in these specific patients.
METHODS: Cross-sectional, multicentre, observational study analysed QOL using a standardised questionnaire in children from 7 to 17 years, with a steroid-dependent or steroid-resistant INS in stable remission. The questionnaire consisted of 30 questions concerning physical and emotional well-being, self-esteem, family, friends, school and disease resulting in a global score of 0-100.
RESULTS: A total of 110 patients with a mean age of 11.6 years from three French paediatric nephrology centres were included. A total of 71 patients had oral immunosuppressive treatment, 27 had RTX, and 12 had both. 13.6% of patients had a steroid-resistant INS. The mean number of relapses was 5.8. Seventy-eight patients answered the questionnaire. The global score in the whole study population was 74.7; 72.6 in the RTX group, 76.2 in the oral drugs group, (P = 0.49). The results of sub-dimension 'school' were statistically lower in RTX group (61.6 ± 19.5) compared with oral drugs group (71.4 ± 16; P = 0.02).
CONCLUSION: Global QOL score was high in 'difficult-to-treat' patients with INS in stable remission on oral immunosuppressive or RTX treatment. ©2019 Foundation Acta Paediatrica. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  children and adolescents; immunosuppression; nephrotic syndrome; quality of life

Year:  2019        PMID: 31240744     DOI: 10.1111/apa.14912

Source DB:  PubMed          Journal:  Acta Paediatr        ISSN: 0803-5253            Impact factor:   2.299


  5 in total

1.  Health-Related Quality of Life in Focal Segmental Glomerular Sclerosis and Minimal Change Disease: A Qualitative Study of Children and Adults to Inform Patient-Reported Outcomes.

Authors:  Noelle E Carlozzi; Susan F Massengill; Howard Trachtman; Liron Walsh; Neena Singhal; Joseph M LaVigne; Jennifer A Miner; Hailey E Desmond; Christian Lynam; Debbie S Gipson
Journal:  Kidney Med       Date:  2021-04-20

2.  Reliability of generic quality-of-life instruments in assessing health-related quality of life among children and adolescents with idiopathic nephrotic syndrome: a systematic review.

Authors:  Ann E Aronu; Samuel N Uwaezuoke; Uzoamaka V Muoneke
Journal:  Health Qual Life Outcomes       Date:  2021-05-12       Impact factor: 3.186

3.  Comparison of rituximab, cyclophosphamide, and tacrolimus as first steroid-sparing agents for complicated relapsing/steroid-dependent nephrotic syndrome in children: an evaluation of the health-related quality of life.

Authors:  Li Wang; Jialiang Zhu; Mingyun Xia; Ran Hua; Fang Deng
Journal:  Arch Med Sci       Date:  2022-01-14       Impact factor: 3.318

4.  Long-term health-related quality of life outcomes of adults with pediatric onset of frequently relapsing or steroid-dependent nephrotic syndrome.

Authors:  Vincent Audard; Hélène Mellerio; Marie-Sophie Meuleman; Sophie Guilmin-Crépon; Aurélie Hummel; Eric Daugas; Agnès Dumas; Fallou Leye; Jacques Dantal; Claire Rigothier; François Provot; Dominique Chauveau; Stéphane Burtey; Alexandre Hertig; Karine Dahan; Antoine Durrbach; Claire Dossier; Alexandre Karras; Dominique Guerrot; Vincent Esnault; Philippe Rémy; Ziad A Massy; Isabelle Tostivint; Marie-Pascale Morin; Philippe Zaoui; Olivier Fritz; Moglie Le Quintrec; Alain Wynckel; Aurélie Bourmaud; Olivia Boyer; Dil Sahali; Corinne Alberti
Journal:  J Nephrol       Date:  2021-07-05       Impact factor: 3.902

5.  Vascular Endothelial Growth Factor (VEGF) and Neopterin Levels in Children with Steroid-sensitive and Steroid-resistant Nephrotic Syndrome.

Authors:  Riska Habriel Ruslie; Darmadi Darmadi; Gontar Alamsyah Siregar
Journal:  Med Arch       Date:  2021-04
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.